Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity
(2022)
Journal Article
Yates, A., Kislitsyna, E., Alfonso Martin, C., Zhang, J., Sewell, A., Goikolea-Vives, A., Cai, V., Alkhader, L., Saland, A., Hammond, B., Dimitrova, R., Batalle, D., Fernandes, C., Edwards, A. D., Gressens, P., Thornton, C., & Stolp, H. (in press). Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity. Journal of Neuroinflammation, https://doi.org/10.1186/s12974-022-02625-5
Encephalopathy of prematurity (EoP) affects approximately 30% of infants born <32 weeks gestation and is highly associated with inflammation in the foetus. Here we evaluated the efficacy of Montelukast, a cysteinyl leukotriene receptor antagonist wid...